WFH Humanitarian Aid Program
The lack of access to care and treatment in developing countries is an urgent and important public health challenge, as the cost of products to treat is prohibitively expensive for the majority of those affected with a bleeding disorder.
The WFH is leading the effort to change this lack of access in developing countries by providing consistent and predictable access to Treatment for All.
1996-2017:
0
2018:
0
TREATMENT FOR ALL
The lack of access to care and treatment in developing countries is an urgent and important public health challenge.
The WFH is leading the effort to change this lack of access by providing consistent and predictable treatment for all people with inherited bleeding disorders.
About the WFH Humanitarian Aid Program
The expanded WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer, our Visionary Contributor; Grifols and Roche, our Leadership Contributors; and our Contributors, CSL Behring and GC Pharma.
CONTRIBUTORS
Founding Visionary
Sanofi/Sobi
Visionary
Bayer
Leadership
Grifols
Roche
Contributors
CSL Behring
GC Pharma
Contributors
The visionary contribution from Bioverativ, a Sanofi company, and Sobi to the WFH Humanitarian Aid Program translates into 500 million IUs over five years (2015-2020). Bioverativ and Sobi also make ongoing substantial financial contributions to support the logistics of product delivery and training of providers and patients in humanitarian aid countries. Furthermore, the eight-year commitment (2014-2021) from Grifols totaling 200 million IUs, along with a ten-year commitment (2009-2018) from CSL Behring for a total of 22 million IUs, and the three-year agreement (2017-2019) with Green Cross for 6 million IUs, allows for a more predictable and sustainable flow of humanitarian aid donations to the global community.
With increased multi-year donations and a steady flow of treatment products to the WFH network, it will be possible for people with bleeding disorders in the developing world to have continued access to treatment for emergency situations, acute bleeds, corrective surgeries, and also prophylaxis (for young children).
The WFH Humanitarian Aid Program also provides a range of integrated care development training programs to ensure the local infrastructure and medical expertise are available to optimize and appropriately use donated products.
WFH Humanitarian Aid Program: Impact Report 2018
The lack of access to care and treatment for people affected with a bleeding disorder in developing countries is an urgent and important public health challenge. Through its Humanitarian Aid Program, the WFH is leading the effort to change this situation in developing countries by providing consistent, predictable, and free access to medical treatment.
“WFH Humanitarian Aid Program: Impact Report 2018” assesses the effect on the ground of the WFH Humanitarian Aid Program. Through key performance indicators, case studies and testimonials, the report presents the real-life effect of the program on our targeted populations while analyzing the progress made in terms of sustainable care on our path to Treatment for All.